English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 914425 Online Users : 1389
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
癌症研究所
陳立宗
--期刊論文
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
國家衛生研究院 NHRI
>
癌症研究所
>
陳立宗
>
期刊論文
>
Browse By Title
Browse By Authors
Browse By Date
Browse By Data Type
Loading...
Siblings
圖書
[
1
/1]
會議論文/會議摘要
[
115
/179]
Collection Statistics
近3年內發表的文件:58(17.58%)
含全文筆數:327(99.09%)
文件下載次數統計
下載大於0次:327(100.00%)
下載大於100次:313(95.72%)
檔案下載總次數:138681(77.76%)
最後更新時間: 2024-12-01 12:22
Top Upload
Loading...
Top Download
Loading...
Recent Submissions
Pan-Asian adapted ESMO clinical pra...
Nivolumab plus chemotherapy in pati...
Survival of advanced/recurrent gast...
Topiramate suppresses peri-infarct ...
A phase 1 study of biweekly nab-pac...
Plain language summary of the FOENI...
Outcomes of post-immunotherapy dura...
Durvalumab or placebo plus gemcitab...
Impact of previous S-1 treatment on...
Chromatin remodeling-related PRDM1 ...
Jump to a point in the index:
(Choose year)
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1985
1980
1975
1970
1960
1950
(Choose month)
January
February
March
April
May
June
July
August
September
October
November
December
Or type in a year:
Ordering With Most Recent First
Show Oldest First
Showing items 41-50 of 330. (33 Page(s) Totally)
<<
<
1
2
3
4
5
6
7
8
9
10
>
>>
View [
10
|
25
|
50
] records per page
Date
Title
Relation
2022-09
Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan
Liver Cancer. 2022 Sep;11(5):426-439.
2022-06-22
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study
Frontiers in Oncology. 2022 Jun 22;12:Article number 800842.
2022-06-02
Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma
Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536.
2022-06
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
Journal of Hepato-Biliary-Pancreatic Sciences. 2022 Jun;54(5):607-612.
2022-05-15
Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience
American Journal of Cancer Research. 2022 May 15;12(5):2189-2202.
2022-05
Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness
Cancer Science. 2022 May;113(5):1601-1612.
2022-04-18
The trinity: Interplay among cancer cells, fibroblasts, and immune cells in pancreatic cancer and implication of CD8(+) T cell-orientated therapy
Biomedicines. 2022 Apr 18;10(4):Article number 926.
2022-04-15
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan
American Journal of Cancer Research. 2022 Apr 15;12(4):1884-1898.
2022-04-11
Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment
Journal of Experimental and Clinical Cancer Research. 2022 Apr 11;41:Article number 137.
2022-04
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
British Journal of Cancer. 2022 Apr;126(7):1018-1026.
Showing items 41-50 of 330. (33 Page(s) Totally)
<<
<
1
2
3
4
5
6
7
8
9
10
>
>>
View [
10
|
25
|
50
] records per page
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback